TNFRSF9 and neoplasm: Intriguingly, combined treatment of anti-TIM-3 and anti-CD137 mAbs significantly increased survival of mice bearing 10 days established tumor with 60% (6 out of 10 mice) of mice tumor free 90 days after tumor injection (Figure 1B; p < 0.01, combined mAb compared to single or control mAb), and even mice succumbed to tumor growth also had significantly prolonged MTS compared with control or single mAb treated mice (Figure 1D; MTS 31.40, 32.80, 32.50 and 73.00 days for control, anti-TIM-3, anti-CD137 and anti-TIM-3/CD137 group; p < 0.01, combined mAb compared to single or control mAb).